-
Novo Nordisk plans to cut 11% of its global workforce, mainly in Denmark, as sales of its obesity drugs slow and competition intensifies. The move aims to reduce costs and refocus R&D, following a sharp decline in market value and increased competition from Eli Lilly and generic manufacturers.
-
On October 10, 2025, President Donald Trump announced a deal with AstraZeneca to lower drug prices for Medicaid patients by matching the lowest prices in developed countries. The agreement includes AstraZeneca's commitment to invest $50 billion in U.S. manufacturing by 2030 and participation in the upcoming TrumpRx website, which will sell discounted drugs directly to consumers starting in early 2026.
-
The US has announced new tariffs on heavy trucks, steel, aluminum, and various finished goods, citing national security. The move affects European and Mexican industries, with concerns over supply chains and trade relations. The tariffs take effect from October 1, 2025, amid ongoing global trade tensions.
-
Pfizer has agreed to acquire Metsera Inc., a biotech developing obesity treatments, for up to $86.25 per share, defeating a rival bid from Novo Nordisk amid a competitive market for weight-loss drugs. The deal follows a bidding war and regulatory concerns.
-
Leading companies including Microsoft, JPMorgan, Walmart, and Goldman Sachs are rapidly expanding their AI initiatives. They focus on in-house model development, workforce training, and integrating AI into operations, amid ongoing debates about job impacts and strategic advantages. The story highlights recent investments, partnerships, and workforce transformations as of November 2025.
-
On December 1-2, 2025, WHO issued its first guidelines recommending long-term use of GLP-1 drugs like Wegovy and Mounjaro for obesity treatment, recognizing obesity as a chronic disease. The US government finalized deals lowering prices for these drugs under Medicare and Medicaid, expanding coverage to more patients. Despite benefits, studies show weight and health gains reverse if treatment stops, highlighting need for ongoing care.
-
Economists warn of five key risks for 2026, including US growth, global manufacturing, political influence on the Fed, AI bubble burst, and rising debt issuance, amid ongoing economic uncertainty and shifting market dynamics.
-
Novo Nordisk's trials of the drug Rybelsus, containing semaglutide, did not meet their primary goal of delaying cognitive decline in early Alzheimer's patients. While some biological processes improved, the studies showed no effect on cognition. Shares fell sharply amid disappointment, though the drug remains beneficial for diabetes and obesity.